• Explore /
  • Poster
  • / Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC).

Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC).

Abstract Poster

Authors

Chigusa Morizane

Chigusa Morizane

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

Chigusa Morizane , Makoto Ueno , Takashi Sasaki , Fumio Nagashima , Nobumasa Mizuno , Satoshi Shimizu , Nozomi Hayata , Hiroki Ikezawa , Takuya Suzuki , Ryo Nakajima , Corina E. Dutcus , Masafumi Ikeda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02579616

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 310)

DOI

10.1200/JCO.2017.35.4_suppl.310

Abstract #

310

Poster Bd #

E2

Abstract Disclosures

Similar Posters

First Author: Jia Fan

First Author: Zhifang Li

First Author: Richard D. Kim

First Author: YunJung Kim